Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of INCB054828 (pemigatinib) in Japanese subjects with advanced malignancies
jRCT2080224150Phase 1Completed
- Sponsor
- Incyte
- Start
- Nov 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pemigatinib in Nonhematologic neoplasms, cancer and metastasis (2 arms), sponsored by Incyte. Primary endpoints: Safety and tolerability of pemigatinib and Determination of recommended Phase 2 dose (RP2D). Started Nov 2018; status: completed.
02
Drugs
pemigatinib
03
Conditions
Nonhematologic neoplasmscancermetastasis
Beyond the preview
Go deeper on jRCT2080224150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224150.